Pyelonephritis medical therapy: Difference between revisions
Jump to navigation
Jump to search
Usama Talib (talk | contribs) |
Usama Talib (talk | contribs) |
||
| Line 21: | Line 21: | ||
===Antimicrobial Therapy=== | ===Antimicrobial Therapy=== | ||
As a broader rule, antibiotics are started only after the sample has been drawn for culture. Uncomplicated pyelonephritis is treated with specific and short duration antibiotics while complicated pyelonephritis is treated with broad spectrum and longer duration of antibiotics.<ref name="pmid22417256">{{cite journal| author=Hooton TM| title=Clinical practice. Uncomplicated urinary tract infection. | journal=N Engl J Med | year= 2012 | volume= 366 | issue= 11 | pages= 1028-37 | pmid=22417256 | doi=10.1056/NEJMcp1104429 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22417256 }} </ref> | As a broader rule, antibiotics are started only after the sample has been drawn for culture. Uncomplicated pyelonephritis is treated with specific and short duration (5 to 14 days) of antibiotics while complicated pyelonephritis is treated with broad spectrum and longer duration (at least 14-21 days) of antibiotics.<ref name="pmid22417256">{{cite journal| author=Hooton TM| title=Clinical practice. Uncomplicated urinary tract infection. | journal=N Engl J Med | year= 2012 | volume= 366 | issue= 11 | pages= 1028-37 | pmid=22417256 | doi=10.1056/NEJMcp1104429 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22417256 }} </ref> | ||
*'''Pyelonephritis empiric therapy''' | *'''Pyelonephritis empiric therapy''' | ||
| Line 30: | Line 30: | ||
::*Alternative regimen (2), regional fluoroquinolone resistance ≥ 10%: [[TMP-SMX]] 160/800 mg PO q12h x 14 days {{and}} ([[Ceftriaxone]] 1 g IV x 1 dose {{or}} [[Gentamicin]] 7 mg/kg IV x 1 dose {{or}} [[Tobramycin]] 7 mg/kg IV x 1 {{or}} [[Amikacin]] 20 mg/kg IV x 1 dose | ::*Alternative regimen (2), regional fluoroquinolone resistance ≥ 10%: [[TMP-SMX]] 160/800 mg PO q12h x 14 days {{and}} ([[Ceftriaxone]] 1 g IV x 1 dose {{or}} [[Gentamicin]] 7 mg/kg IV x 1 dose {{or}} [[Tobramycin]] 7 mg/kg IV x 1 {{or}} [[Amikacin]] 20 mg/kg IV x 1 dose | ||
::*Alternative regimen (3): ([[Amoxicillin-clavulanate potassium|Amoxicillin–Clavulanate]] 500/125 mg PO q12h x 14 days {{or}} [[Amoxicillin-clavulanate potassium|Amoxicillin–Clavulanate]] 250/125 mg PO q8h x 5–7 days {{or}} [[Cefaclor]] 500 mg PO q8h x 7 days) {{and}} ([[Ceftriaxone]] 1 g IV in a single dose {{or}} [[Gentamicin]] 7 mg/kg IV in a single dose {{or}} [[Tobramycin]] 7 mg/kg IV in a single dose {{or}} [[Amikacin]] 20 mg/kg IV in a single dose ) | ::*Alternative regimen (3): ([[Amoxicillin-clavulanate potassium|Amoxicillin–Clavulanate]] 500/125 mg PO q12h x 14 days {{or}} [[Amoxicillin-clavulanate potassium|Amoxicillin–Clavulanate]] 250/125 mg PO q8h x 5–7 days {{or}} [[Cefaclor]] 500 mg PO q8h x 7 days) {{and}} ([[Ceftriaxone]] 1 g IV in a single dose {{or}} [[Gentamicin]] 7 mg/kg IV in a single dose {{or}} [[Tobramycin]] 7 mg/kg IV in a single dose {{or}} [[Amikacin]] 20 mg/kg IV in a single dose ) | ||
::*Alternative regimen (4):TMP-SMX, 160mg and 800mg, twice daily for 3 days | |||
::*Alternative regimen (5):Fosfomycin, a single dose of 3g | |||
:*'''Inpatient treatment'''<ref name="pmid21292654">{{cite journal| author=Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG et al.| title=International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. | journal=Clin Infect Dis | year= 2011 | volume= 52 | issue= 5 | pages= e103-20 | pmid=21292654 | doi=10.1093/cid/ciq257 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21292654 }} </ref> | :*'''Inpatient treatment'''<ref name="pmid21292654">{{cite journal| author=Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG et al.| title=International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. | journal=Clin Infect Dis | year= 2011 | volume= 52 | issue= 5 | pages= e103-20 | pmid=21292654 | doi=10.1093/cid/ciq257 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21292654 }} </ref> | ||
::*Preferred regimen: [[Ciprofloxacin]] 400 mg IV q12h for 10-14 days {{or}} [[Levofloxacin]] 750 mg IV q24h for 10-14 days | ::*Preferred regimen: [[Ciprofloxacin]] 400 mg IV q12h for 10-14 days {{or}} [[Levofloxacin]] 750 mg IV q24h for 10-14 days | ||
Revision as of 15:53, 24 January 2017
|
Pyelonephritis Microchapters |
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Pyelonephritis medical therapy On the Web |
|
American Roentgen Ray Society Images of Pyelonephritis medical therapy |
|
Risk calculators and risk factors for Pyelonephritis medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
All patients with pyelonephritis should be treated empirically with antimicrobial therapy. Mild pyelonephritis may be managed with oral antimicrobial therapy, and an initial intravenous dose may be administered depending on local resistance patterns. Patients with dehydration, nausea, vomiting, or signs of sepsis should be admitted and should receive parenteral therapy. Medical therapies for pyelonephritis include fluoroquinolones, TMP-SMX, β-lactams, and aminoglycosides. [1]
PMID: Ecoli resistance: 23926177 , 23926176 and 25048850 and 9098661 and 23465025
Medical Therapy
The medical therapy for pyelonephritis has a few important aspects to be kept in mind:[1]
- All patients with pyelonephritis should be treated empirically with antimicrobial therapy.
- Before initiating antimicrobial treatment for suspected pyelonephritis, a urine culture and susceptibility test should always be performed.
- Mild pyelonephritis may be managed with oral antimicrobial therapy, and an initial intravenous dose may be administered depending on local resistance patterns. Patients with dehydration, nausea, vomiting, or signs of sepsis should be admitted and should receive parenteral therapy.[2]
- Optimal management depends on the severity of illness at presentation, regional resistance data, and host factors.
- When local resistance patterns are unknown, an initial intravenous (IV) dose of a long-acting, broad-spectrum antimicrobial agent may be considered.
- Oral beta-lactams are less effective than either trimethoprim-sulfamethoxazole, fluoroquinolones, or aminoglycosides in eradicating uropathogens.
- Uncomplicated pyelonephritis due to MRSA is uncommon, and there is insufficient evidence to support empiric use of an MRSA-active agent.
- Pregnant women, patients who failed to respond to oral therapy, and patients with nausea, vomiting, high fever, marked leukocytosis, or dehydration should be hospitalized and managed with parenteral antibiotics.[3]
Antimicrobial Therapy
As a broader rule, antibiotics are started only after the sample has been drawn for culture. Uncomplicated pyelonephritis is treated with specific and short duration (5 to 14 days) of antibiotics while complicated pyelonephritis is treated with broad spectrum and longer duration (at least 14-21 days) of antibiotics.[4]
- Pyelonephritis empiric therapy
- Outpatient treatment
- Preferred regimen, regional fluoroquinolone resistance < 10%: Ciprofloxacin 500 mg PO q12h x 7 days ± 400 mg IV in a single dose OR Ciprofloxacin XR 1000 mg PO q24h for 7 days OR Levofloxacin 750 mg PO q24h for 5 days
- Preferred regimen, regional fluoroquinolone resistance ≥ 10%: (Ciprofloxacin 500 mg PO q12h x 7 days ± 400 mg IV in a single dose OR Ciprofloxacin XR 1000 mg PO q24h for 7 days OR Levofloxacin 750 mg PO q24h for 5 days) AND (Ceftriaxone 1 g IV x 1 dose OR Gentamicin 7 mg/kg IV x 1 dose OR Tobramycin 7 mg/kg IV x 1 dose OR Amikacin 20 mg/kg IV x 1 dose)
- Alternative regimen (1), regional fluoroquinolone resistance < 10%: TMP-SMX 160/800 mg PO q12h x 14 days
- Alternative regimen (2), regional fluoroquinolone resistance ≥ 10%: TMP-SMX 160/800 mg PO q12h x 14 days AND (Ceftriaxone 1 g IV x 1 dose OR Gentamicin 7 mg/kg IV x 1 dose OR Tobramycin 7 mg/kg IV x 1 OR Amikacin 20 mg/kg IV x 1 dose
- Alternative regimen (3): (Amoxicillin–Clavulanate 500/125 mg PO q12h x 14 days OR Amoxicillin–Clavulanate 250/125 mg PO q8h x 5–7 days OR Cefaclor 500 mg PO q8h x 7 days) AND (Ceftriaxone 1 g IV in a single dose OR Gentamicin 7 mg/kg IV in a single dose OR Tobramycin 7 mg/kg IV in a single dose OR Amikacin 20 mg/kg IV in a single dose )
- Alternative regimen (4):TMP-SMX, 160mg and 800mg, twice daily for 3 days
- Alternative regimen (5):Fosfomycin, a single dose of 3g
- Inpatient treatment[5]
- Preferred regimen: Ciprofloxacin 400 mg IV q12h for 10-14 days OR Levofloxacin 750 mg IV q24h for 10-14 days
- Alternative regimen (1): Gentamicin 7 mg/kg IV q24h for 10-14 days ± Ampicillin 500 mg IV q6h for 10-14 days
- Alternative regimen (2): Tobramycin 7 mg/kg IV q24h for 10-14 days ± Ampicillin 500 mg IV q6h for 10-14 days
- Alternative regimen (3): Amikacin 20 mg/kg IV q24h for 10-14 days ± Ampicillin 500 mg IV q6h for 10-14 days
- Alternative regimen (4): Cefotaxime 1-2 g IV q8h for 10-14 days ± (Gentamicin 7 mg/kg IV q24h for 10-14 days OR Tobramycin 7 mg/kg IV q24h for 10-14 days OR Amikacin 20 mg/kg IV q24h for 10-14 days)
- Alternative regimen (5): Ceftriaxone 1 g IV q24h ± (Gentamicin 7 mg/kg IV q24h for 10-14 days OR Tobramycin 7 mg/kg IV q24h for 10-14 days OR Amikacin 20 mg/kg IV q24h for 10-14 days)
- Alternative regimen (6): Ceftazidime 12 g IV q8h ± (Gentamicin 7 mg/kg IV q24h for 10-14 days OR Tobramycin 7 mg/kg IV q24h for 10-14 days OR Amikacin 20 mg/kg IV q24h for 10-14 days)
- Alternative regimen (7): Ampicillin-Sulbactam 1.5 g IV q6h ± (Gentamicin 7 mg/kg IV q24h for 10-14 days OR Tobramycin 7 mg/kg IV q24h for 10-14 days OR Amikacin 20 mg/kg IV q24h for 10-14 days)
- Alternative regimen (8): Piperacillin-Tazobactam 3.375 g IV q4-6h ± (Gentamicin 7 mg/kg IV q24h for 10-14 days OR Tobramycin 7 mg/kg IV q24h for 10-14 days OR Amikacin 20 mg/kg IV q24h for 10-14 days)
- Alternative regimen (9): Ticarcillin-Clavulanate 3.1 g IV q4-6h ± (Gentamicin 7 mg/kg IV q24h for 10-14 days OR Tobramycin 7 mg/kg IV q24h for 10-14 days OR Amikacin 20 mg/kg IV q24h for 10-14 days)
- Alternative regimen (10): Meropenem 500 mg IV q8h for 10-14 days
- Alternative regimen (11): Ertapenem 1 g IV q24h for 10-14 days
- Alternative regimen (12): Doripenem 500 mg IV q8h for 10-14 days
- Alternative regimen (13): Aztreonam 1 g IV q8-12h for 10-14 days
- Pathogen-directed therapy[5]
- Enterococcus spp.[5]
- Preferred regimen: Ampicillin 2 g IV q6h for 10-14 days AND Gentamicin 3-5 mg/kg/day IV q8h for 10-14 days
- Specific considerations
- Pregnancy[6]
- Pyelonephritis empiric therapy
- Preferred regimen (1): Ceftriaxone 1-2 g IV/IM q24h for 10-14 days
- Preferred regimen (2): Aztreonam 1 g IV q8-12h for 10-14 days
- Preferred regimen (3): Piperacillin-Tazobactam 3.375-4.5 g IV q6h for 10-14 days
- Preferred regimen (4): Imipenem-Cilastatin 500 mg IV q6h for 10-14 days
- Note: Fluoroquinolones and aminoglycosides should be avoided in pregnant patients
References
- ↑ 1.0 1.1 Ramakrishnan K, Scheid DC (2005). "Diagnosis and management of acute pyelonephritis in adults". Am Fam Physician. 71 (5): 933–42. PMID 15768623.
- ↑ Gupta, K.; Hooton, TM.; Naber, KG.; Wullt, B.; Colgan, R.; Miller, LG.; Moran, GJ.; Nicolle, LE.; Raz, R. (2011). "International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 up
date by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases". Clin Infect Dis. 52 (5): e103–20. doi:10.1093/cid/ciq257. PMID 21292654. Unknown parameter
|month=ignored (help); line feed character in|title=at position 132 (help) - ↑ Warren, JW.; Abrutyn, E.; Hebel, JR.; Johnson, JR.; Schaeffer, AJ.; Stamm, WE. (1999). "Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA)". Clin Infect Dis. 29 (4): 745–58. doi:10.1086/520427. PMID 10589881. Unknown parameter
|month=ignored (help) - ↑ Hooton TM (2012). "Clinical practice. Uncomplicated urinary tract infection". N Engl J Med. 366 (11): 1028–37. doi:10.1056/NEJMcp1104429. PMID 22417256.
- ↑ 5.0 5.1 5.2 Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG; et al. (2011). "International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases". Clin Infect Dis. 52 (5): e103–20. doi:10.1093/cid/ciq257. PMID 21292654.
- ↑ "http://www.uroweb.org/gls/pdf/18_Urological%20infections_LR.pdf" (PDF). External link in
|title=(help)